Cerebral blood flow and metabolic abnormalities in Alzheimer's disease

Annals of Nuclear Medicine

Volumn 15, Issue 2, 2001, Pages 85-92

  Matsuda, H ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

Author keywords

Alzheimer's disease; Metabolic rate for glucose; PET; Regional cerebral; Regional cerebral blood flow; SPECT

Indexed keywords

APOLIPOPROTEIN E; DONEPEZIL;

ALLELE; ALZHEIMER DISEASE; ASSOCIATION CORTEX; BRAIN BLOOD FLOW; CINGULATE GYRUS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE COURSE; ENTORHINAL CORTEX; GENOTYPE; HUMAN; LANGUAGE; MEMORY; METABOLISM; NERVE CELL DEGENERATION; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0034983181     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02988596     Document Type: Review

References (100)

1. An automated method for rotational correction and centering of three-dimensional functional brain images
2. Automated detection of the intercommissural (AC-PC) line for stereotactic localization of functional brain images
3. Anatomical standardization: Linear scaling and nonlinear warping of functional brain images
4. Principles and methods
5. Prospects for pharmacological intervention in Alzheimer disease
6. 18F]fluorodeoxyglucose
7. Alzheimer's disease: Focal cortical changes shown by positron emission tomography
8. Imaging local brain function with emission computed tomography
9. Cortical abnormalities in Alzheimer's disease
10. Patterns of cerebral glucose utilization in depression, multiple infarct dementia, and Alzheimer's disease
11. Clinical history, brain metabolism, and neuropsychological function in Alzheimer's disease
12. Alzheimer's disease: Anterior-posterior and lateral hemispheric alterations in cortical glucose utilization
13. PET in Alzheimer's disease
14. Positron emission tomography in patients with clinically diagnosed Alzheimer's disease
15. Dominantly inherited Alzheimer's disease: Cerebral glucose metabolism
16. Single photon emission computed tomography in Alzheimer's disease: Abnormal iofetamine I 123 uptake reflects dementia severity
17. Criteria for the diagnosis of Alzheimer's disease with PET
18. Abnormalities of energy metabolism in Alzheimer's disease studies with PET
19. Functional brain imaging and Alzheimer-type dementia
20. 11C-deoxyglucose accumulation, CSF monoamine metabolites and neuropsychological test performance in patients and healthy subjects
21. Differences of regional cerebral glucose metabolism between presenile and senile dementia of Alzheimer type
22. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET
23. NIH Conference. Brain imaging: Aging and dementia
24. Differences in lateral hemispheric asymmetries of glucose utilization between early- and late-onset Alzheimer-type dementia
25. Fluorine-18-fluorodeoxyglucose positron emission tomography studies in presumed Alzheimer cases, including 13 serial scans
26. Cerebral metabolic and cognitive studies in dementia with frontal lobe behavioral features
27. Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type
28. Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease. Pathophysiologic implications
29. Longitudinal changes in cognitive function and regional cerebral function in Alzheimer's disease: A SPECT blood flow study
30. Longitudinal SPECT study in Alzheimer's disease: Relation to apolipoprotein E polymorphism
31. Distribution of cerebral degeneration in Alzheimer's disease. A clinico-pathological study
32. Alzheimer's disease: Cell-specific pathology isolates the hippocampal formation
33. Neuropathological staging of Alzheimer-related changes
34. Staging of Alzheimer's disease-related neurofibrillary changes
35. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease
36. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease
37. MR1 of entorhinal cortex in mild Alzheimer's disease
38. Cognitive deficits and clinical diagnosis of Alzheimer's disease
39. Detection and staging of demential in Alzheimer's disease: Use of the neuropsychological measures developed for the consortium to establish a registry for Alzheimer's disease
40. Quantitative changes in mesial temporal volume, regional cerebral blood flow, and cognition in Alzheimer's disease
41. High-resolution SPECT to assess hippocampal perfusion in neuropsychiatric diseases
42. MRI-guided SPECT measurements of medial temporal lobe blood flow in Alzhemer's disease
43. 99mTc-HMPAO regional cerebral blood flow and quantitative electroencephalography in Alzheimer's disease: A correlative study
44. Longitudinal evaluation of early Alzheimer's disease using brain perfusion SPECT
45. MRI-based volumetry of hippocampal gray-matter, and SPECT measurements of hippocampal blood flow for the diagnosis of Alzheimer's disease: Comparison with Statistical Parametric Mapping
46. Decreased medial temporal oxygen metabolism in Alzheimer's disease shown by PET
47. Paradoxical hippocampus perfusion in mild-to-moderate Alzheimer's disease
48. Time course of changes in lactate and free fatty acids after experimental brain injury and relationship to morphologic damage
49. Posterior cingulate cortex in Alzheimer's disease
50. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease
51. Preclinical prediction of Alzheimer's disease using SPECT
52. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease
53. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease
54. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease
55. Principles and Applications for the Brain and Heat
56. Neocortical and hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and perirhinal cortices in the non-human primate as shown by PET. Implications for Alzheimer's disease
57. The neural substrates of memory systems impairment in Alzheimer's disease. A PET study of resting brain glucose utilization
58. Brain system for encoding and retrieval of auditory-verbal memory
59. Selective impairment of memory and visual perception in splenial tumours
60. Retrosplenial amnesia
61. A proposed mechanism of emotion
62. Attention and executive deficits in Alzheimer's disease. A critical review
63. Visual attention impairments in Alzheimer's disease
64. The effect of divided attention on encoding and retrieval in episodic memory revealed by positron emission tomography
65. Selective and divided attention during Visual Discrimination of shape, color, and speed: Functional anatomy by positron emission tomography
66. 15O PET
67. 18F scan in Alzheimer's disease and multi-infarct dementia
68. Preserved pontine glucose metabolism in Alzheimer disease: A reference region for functional brain image (PET) analysis
69. Reduction of cerebellar glucose metabolism in advanced Alzheimer's disease
70. Apolipoprotein E: Structure-function relationship
71. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
72. Distribution of apolipoprotein E gene polymorphisms in Japanese patients with Alzheimer's disease and in Japanese centenarians
73. Influence of the Apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease
74. Apolipoprotein E, dementia, and cortical deposition of β-amyloid protein
75. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition
76. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E
77. Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer's disease
78. Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease
79. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease
80. Apolipoprotein E genotype and progression of Alzheimer's disease: The Rotterdam Study
81. No difference in cerebral glucose metabolism in patients with Alzheimer's disease and differing apolipoprotein E genotypes
82. Lack of association of apolipoprotein E epsilon4 allele dose with cerebral glucose metabolism in Alzheimer disease
83. Gene dose of the epsilon 4 allele of apolipoprotein E and disease progression in sporadic late-onset Alzheimer's disease
84. Absence of an apolipoprotein E epsilon4 allele is associated with increased parietal regional cerebral blood flow asymmetry in Alzheimer disease
85. The absence of an apolipoprotein ε4 allele is associated with a more aggressive form of Alzheimer disease
86. Decreased hippocampal volume asymmetry on MRIs in nondemented elderly subjects carrying the apolipoprotein E ε4 allele
87. Reduced size of right hippocampus in 39- to 80-year-old normal subjects carrying the apolipoprotein E ε4 allele
88. SPECT and MRI analysis in Alzheimer's disease: Relation to the apolipoprotein E ε4 allele
89. Apolipoprotein E gene in diffuse Lewy body disease with or without co-existing Alzheimer's disease
90. Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease
91. The cholinergic hypothesis of Alzheimer's disease: A review of progress
92. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
93. Donepezil improves cognition and global function in Alzheimer disease
94. Visual form of Alzheimer's disease and its response to anticholinesterase therapy
95. Orbital and dorsolateral frontal perfusion defect associated with behavioral response to cholinesterase inhibitor therapy in Alzheimer's disease
96. Changes in the rCBF images of patients with Alzheimer's disease receiving Donepezil therapy
97. Design and evaluation of radioactive acetylcholine analogs for mapping brain acetylcholinesterase (AchE) in vivo
98. In vivo mapping of cerebral acetylcholinestrase acitivity in aging and Alzheimer's disease
99. Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: A positron emission tomography study
100. Limited donepezil inhibition of acetylcholinesterase measured by positron emission tomography in living Alzheimer cerebral cortex